Rimonabant in Diabetes: This weight-loss, anti-smoking drug targets multiple risk factors in diabetics
In this trial, individuals with type 2 diabetes were randomized to receive either 5 mg of rimonabant, 20 mg of rimonabant, or placebo. All patients were on non-insulin diabetic therapy (metformin or a sulfonylurea drug). The group taking the higher dose of rimonabant had the greatest reductions in weight and waist size. Their hemoglobin A1C levels were significantly decreased, a finding which reflects improved glucose control. They also had significantly improved HDL cholesterol and triglyceride levels, and reduced systolic blood pressure.
Happy Grandmommy to Amanda, Alayna, Wyatt and Ezekiel
Post Edited (Kathlyn1950) : 7/18/2005 8:25:14 AM (GMT-6)